Jiangsu Hengrui Medicine Company Ltd.

Wuxi Grandchamp Pharmaceutical Technology Co., Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Jiangsu Hansoh Pharmaceuticals Co., Ltd.

Changan Sun

Aifeng Lv

Yali Wang

Tao Jiang

Aifeng Lü

Ruijun Wang

Hengli Yuan

Piaoyang Sun

Lianshan Zhang

Jijun Yuan

Jiajian Liu

Chunqian Fang

Wang Yali

Wentao Wu

Aifeng Lu

Hongwei Tang

Aifeng Lue

Aifeng LÜ

The present invention relates to a crystal form of a potassium-competitive acid blocker, that is, 1-[5-(2-fluorophenyl)-1-(pyridine-3-sulfonyl)-1H-pyrrole-3-yl]-N-methyl methylamine fumaric acid salt (which is briefly referred to as a formula I) and a preparation method thereof. An X-ray powder diffraction characteristic peak thereof is shown in FIG.. The crystal form that is represented by formula I, provided in the present invention, is stable, reproducible, and is suitable for drug development. 

Crystal form of a potassium-competitive acid blocker and preparation method thereof

The present invention provides a human insulin analog, an acylated derivative thereof and a physiologically acceptable salt. The present invention further provides a preparation method for the insulin analog and an application of the insulin analog as a therapeutic agent, and particularly as a diabetes mellitus therapeutic agent.

Human insulin analogue and acylated derivative thereof

The present invention discloses a modified exendin or pharmaceutically acceptable salts thereof, wherein the modified exendin comprises an amino acid sequence having at least 90% sequence identity to SEQ ID No. 17 and the amino acid sequence has a higher stability than the non-modified exendin of SEQ ID No. 4. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.

Modified exendins and uses thereof

What is provided is EPO mimetic peptide derivatives defined as formula (I) and their pharmaceutical salts, the preparation thereof, wherein R, R, R, R, R, n, nare defined as described in description. A composition comprising of an EPO mimetic peptide derivative defined as formula (I) and its pharmaceutical salt. The uses of the derivatives and their pharmaceutical salts, as well as the uses of the compositions described above in treatment of diseases characterized by a deficiency of EPO or a low or defective red blood cell population.R&#x2014;R&#x2014;(CH)&#x2014;R&#x2014;(CH)&#x2014;R&#x2014;R&#x2003;&#x2003;(I)

Erythropoietin mimetic peptide derivative and its pharmaceutical salts, the preparation and uses thereof

Provided are a G-CSF and water-soluble polymer conjugate, or a pharmaceutically acceptable salt thereof, comprising a water-soluble polymer, a protein, and a linking group; a method for preparing thereof; and a pharmaceutical composition comprising the same.

G-CSF and water-soluble polymer conjugate

This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity.X-X-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X-Ser-X-X-X-Glu-X-X-Ala-X-X-X-Phe-Ile-X-Trp-Leu-X-X-X-X-X-X-X-X-X-X-X-X-X-Lys&#x2003;&#x2003;Formula (I)&#x2014;SEQ ID NO: 238

GLP-1 analogues and their pharmaceutical salts and uses

Novel exendins with modifications at one or more of following positions: 2, 14, 27 or 28 and polyethylene glycol derivatives thereof are provided. These compounds are useful in treating type 2 diabetes as GLP-1 receptor agonists.

Modified exedins and uses thereof

Growing community of inventors

Jiangsu, China

Changan Sun